High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.
Drug Discov Today
; 26(10): 2439-2444, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1242920
ABSTRACT
In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, a panel of assays has been developed and applied to screen collections of approved and investigational drugs for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity in a quantitative high-throughput screening (qHTS) format. In this review, we applied data-driven approaches to evaluate the ability of each assay to identify potential anti-SARS-CoV-2 leads. Multitarget assays were found to show advantages in terms of accuracy and efficiency over single-target assays, whereas target-specific assays were more suitable for investigating compound mechanisms of action. Moreover, strict filtering with counter screens might be more detrimental than beneficial in identifying true positives. Thus, developing novel HTS assays acting simultaneously against multiple targets in the SARS-CoV-2 life cycle will benefit anti-COVID-19 drug discovery.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
High-Throughput Screening Assays
/
Drug Development
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
J.drudis.2021.05.012
Similar
MEDLINE
...
LILACS
LIS